{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-024363","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2026-05-19T12:38:18+00:00","discovered_at":"2026-05-19T12:40:00.291064+00:00","generated_at":"2026-05-19T12:41:07.516388+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device","bullets":["Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.","Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.","Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).","Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024363","json":"https://secwatch.observer/filing/0001493152-26-024363.json","markdown":"https://secwatch.observer/filing/0001493152-26-024363.md","text":"https://secwatch.observer/filing/0001493152-26-024363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/0001493152-26-024363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T12:41:07.516388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}